A landmark UK study involving over 43,000 patients has identified a specific gene variant tied to severe outcomes in inflammatory bowel disease. The allele HLA-DRB1*01:03 is associated with more aggressive disease behavior across both Crohn's disease and ulcerative colitis.
Researchers found that patients carrying this variant faced significantly higher risks. In Crohn's disease, it was linked to increased odds of colonic resection, perianal disease, and advanced therapy use. The associations were even stronger in ulcerative colitis, with a nearly doubled risk for colectomy.
The study also showed the gene influences disease timing. In Crohn's, carriers had older disease onset, while in ulcerative colitis, onset was younger.
Critically, the variant predicted a faster disease course. Carriers developed complications like perianal disease and required surgery sooner. They also escalated to advanced therapies more quickly and had a higher risk of those therapies failing.
These findings suggest HLA-DRB1*01:03 could serve as a genetic marker for severe IBD, not just for getting the disease. If validated, it may allow doctors to identify high-risk patients earlier for closer monitoring and more aggressive treatment.